Medicus Pharma Ltd. has announced the submission of a Type C meeting request to the U.S. Food and Drug Administration (FDA) as part of its efforts to fast-track the clinical development program for treating Basal Cell Carcinoma $(BCC)$ of the skin using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA). The meeting, anticipated for the week of October 6th, 2025, aims to discuss the D-MNA product development and secure the FDA's consent to accelerate the clinical pathway. The company is seeking the FDA's feedback on various aspects, including the selected doses for future studies and the appropriateness of the primary endpoint for upcoming trials. This development is a significant step in Medicus Pharma's ongoing regulatory review process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.